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Permeability is a crucial property of orally administered drugs. Therefore, in drug discovery, it 
is important to employ methods suitable for rapidly and reliably screening of the permeability 
of large numbers of new drug candidates.  
The PVPA, a model consisting of a tight layer of liposomes immobilized on a filter, offers 
potential advantages unmet by other methods and has been successfully used in permeability 
testing of novel active substances as well as formulations. In this study, the PVPA was 
developed into a more robust, biomimetic model by employing a lipid composition matching 
that of the intestinal permeation barrier and performing the experiments at the more biologically 
relevant pH 6.2. 
As expected, positively charged basic compounds demonstrated increased permeability through 
the negatively charged biomimetic barriers, and the degree of correct classification according 
to in vivo absorption was comparable between the original PVPA and the biomimetic PVPA. 
The biomimetic PVPA further proved to be tremendously more robust towards the presence of 
tensides compared to the original PVPA; this is a promising finding that renders the biomimetic 
PVPA an enhanced ability to estimate the permeability of poorly soluble compounds. Hence, 
the PVPA model developed in this study has evolved an important step forward.  
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Assessment of the oral bioavailability of new drug candidates in the early stages of drug 
development is of special interest since modern drug discovery regimens produce hundreds of 
thousands of potential drug candidates for high-throughput screening for activity or potency 
related characteristics. There is thus a rapidly increasing demand for in vitro models that can 
reliably assess drug absorption and disposition, preferably in a high-throughput test format.  
Both in silico and experimental methods are currently available for the prediction and/or 
screening of properties related to oral drug absorption. The gold standard in in vitro 
permeability screening is currently the cell-based Caco-2 model, which is widely established in 
both academia and industry.1-3 This model is of special value in estimating the impact of active 
transport proteins on the permeability of orally administered drugs. However, cell-based 
models, such as the Caco-2 model or the novel method of co-culturing three different cell lines 
to obtain a more complete picture of oral absorption,4 might be too complicated and time-
consuming in regard to modern high-throughput requirements. One of the most commonly used 
current techniques for the rapid screening of drug permeability through the intestinal epithelia 
is the parallel artificial membrane permeation assay (PAMPA).5-10 PAMPA uses a simple 
phospholipid/organic solvent-coated filter as the permeability barrier, which allows for 
medium- to high-throughput screening of permeability properties. Such simplified permeability 
approaches model only the passive pathway, not paracellular or active transport pathways. 
However, reports conclude that 80-95% of the commercial drugs are absorbed primarily by 
passive diffusion.11 Therefore, a robust model focused on passive diffusion, not relying on cells 
and thus more compatible with high-throughput applications appears to be a useful first step in 
the biopharmaceutical characterization of new chemical entities.  
We originally reported the PVPA, a predictive medium- to high-throughput screening method 
for passive drug permeability based on a tight barrier of liposomes on a filter support.12 To the 
best of our knowledge, this was the first successful attempt to deposit a lipid-based membrane 
barrier without the use of an inert solvent, such as hexadecane. The PVPA barriers were 
originally prepared from egg phosphatidylcholine liposomes placed onto a filter support by 
centrifugation. Solvent evaporation and freeze-thaw cycling were then used to promote 
liposome fusion, resulting in a tight barrier consisting of layers of liposomes mimicking a cell-
layer/tissue. The PVPA was validated using a selection of compounds and the apparent 
permeability coefficients obtained correlated well with literature data on human absorption in 
vivo, which suggested that the method is suitable for rapidly screening of the passive transport 
of drugs and new chemical entities.12 The PVPA approach appears to, under comparable 
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settings, mimic in vivo absorption better than the biomimetic PAMPA model8 and performs 
equally well in comparison with the Caco-2 cell model13 and the double sink PAMPA (DS-
PAMPA) model5 in predicting the passive diffusion of drug compounds.12 The model has 
further been shown to be adaptable to automation using a laboratory robotic system14 and is 
stable at –80 C for up to two weeks,15 drastically increasing throughput. The functionality of 
the barriers has also been demonstrated to be stable within a pH range of 2.0 to 8.0, which 
makes the barriers suitable for further studies to provide, for example, insight into segmental 
absorption in the human gastrointestinal tract or to mimic other absorption barriers with a pH 
environment different from pH 7.4.15 The PVPA has further been used to test the permeability 
of new active substances as well as drugs in formulations. The oral permeability of antibacterial 
peptides has been predicted16-18 and different formulations, i.e., micelles, solid solutions and 
liposomes, have been tested in our model.19,20 Recently, a modified PVPA mimicking healthy 
and compromised skin barriers has been introduced.21 
The goal of an in vitro permeability model is the ability to predict permeability values that 
correlate well with in vivo permeability data. To accomplish this, it is important that the model 
mimics the in vivo situation as closely as possible. Factors receiving much attention in this 
respect include the pH profile of the gastrointestinal tract and the lipid composition of the 
artificial barriers. It has been shown that membranes consisting of only phosphatidylcholine 
(PC) underestimate the permeability of basic and acidic drugs and a better in vivo-in vitro 
correlation can be obtained using a negatively charged barrier with a biomimetic lipid 
composition.8,22  
Furthermore, an increasing problem in drug development is that a large number of new drug 
candidates demonstrate low water solubility, which may result in problems pertaining to 
permeability and bioavailability. To overcome this challenge, solubility-increasing agents can 
be added to the donor phase to increase drug solubility. It is therefore also important that a 
permeability model maintains its integrity in the presence of the solubility-enhancing agents of 
interest. 
The aim of this study was thus to improve the biomimetic properties of the PVPA model by 
first investigating if the use of more biologically relevant pH conditions in the permeability 
experiments would lead to improved prediction of in vivo absorption. Second, a biomimetic 
lipid composition was designed to better mimic the intestinal barrier in an effort to significantly 
influence the permeation of drugs. A change in the lipid composition could potentially provide 
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a more robust barrier capable of handling harsher conditions, which in turn would enable an 
estimation of the permeability of poorly soluble compounds. Finally, the stability of the 
biomimetic PVPA in the presence of tensides and co-solvents was investigated. 
 
MATERIALS AND METHODS 
Materials 
Egg phosphatidylcholine, Lipoid E-80, egg phosphatidylethanolamine (EPE) and egg 
phosphatidylserine (EPS) were obtained from Lipoid, Ludwigshafen, Germany. Cholesterol, 
phosphatidylinositol (PI), methanol, alprenolol hydrochloride, atenolol, acebutolol 
hydrochloride, caffeine, chloramphenichol, chlorothiazide, enalapril maleate, 
hydrochlorothiazide, metoprolol tartrate, nadolol, ranitidine hydrochloride, sulphasalazine, 
sulpiride, testosterone, terbutaline hemisulfate, timolol maleate, tranexamic acid, calcein, 
ibuprofen, flufenamic acid, flubiprofen and metronidazole were purchased from Sigma-Aldrich 
Co., St. Louis, MO, USA. Amiloride hydrochloride and chloroform were supplied by Merck 
KGaA, Darmstadt, Germany. Salicylic acid and acetyl salicylic acid were obtained from NMD, 
Oslo, Norway. Cimetidine was purchased from Allphamed Pharma GmbH, Göttingen, 
Germany.  
Propranolol hydrochloride was purchased from TCI Europe N.V., Zwijndrecht, Belgium. 
Diclofenac sodium was purchased from AWD Pharma GmbH & Co., KG, Dresden Germany. 
Filter inserts (Transwell, d=6.5 mm) and plates were purchased from Corning Inc., Corning, 
NY, USA, and the mixed cellulose ester filters (0.65 µm pore size) were obtained from 
Millipore, Billerica, MA, USA.   
 
Liposome preparation 
Liposomes were prepared using the film hydration method. Lipids were dissolved in a mixture 
of chloroform and methanol (2:1) in a round bottom flask. The organic solvent was removed 
under vacuum at 45 °C. The deposited lipid film was exposed to a vacuum of 55 hPa at room 
temperature for an additional 3 h period to remove all traces of solvent prior to hydration with 
phosphate buffer containing 10% (v/v) ethanol, thereby yielding a 6% (w/v) liposomal 
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dispersion as previously described.12 The liposomes were then extruded by hand using either 
syringe filter holders or Lipofast (Avestin Europe GmbH, Mannheim, Germany). 
Liposome size distributions were measured using photon correlation spectroscopy (PCS) in a 
Submicron Particle Sizer 370 (PSS Nicomp Particle Sizing Systems, Santa Barbara, CA, USA). 
Sample preparation and measuring conditions were as previously described.23 Three cycles of 
15-min measurements were performed. 
Zeta potential measurements were performed on liposome dispersions diluted in PBS pH 7.4 
using a Malvern Zetasizer nano Z (Malvern, Worcestershire, UK). 
 
The original preparation method for the PVPA barriers 
The PVPA barriers were prepared according to the procedure previously described12 and were 
stored for up to two weeks at – 80 °C, in accordance with previous stability studies.15 In brief, 
liposome dispersions with a mean size of 300 nm (volume weight) and 600 nm (number weight) 
were deposited on a filter support by centrifugation. The liposomes were added in consecutive 
steps from smallest to largest. Freeze-thaw cycling was then used to promote fusion of the 
liposomes and hence produce a tight barrier.12 
 
Permeation studies 
Permeation studies were performed using solutions of drugs or hydrophilic markers in 
phosphate buffer (pH 7.4 or 6.2), according to the procedure previously described.12 Briefly, 
inserts were loaded with drug solution (100 µL) and placed in separate acceptor compartments 
containing phosphate buffer (600 µL). During the first 3 h of the study, the loaded inserts were 
moved to wells containing equal quantities of fresh buffer at 1 h intervals; over the subsequent 
2 h, the inserts were moved at 0.5 h intervals. For cimetidine, nadolol, chlorothiazide and 
hydrochlorothiazide, the inserts were moved every second hour for 12 h. At the end of the 
permeation experiment, samples (200 L) from each acceptor compartment (5 wells for each 
insert) were transferred into 96-well titer plates for analysis. Samples from the permeation 
experiments with drugs were measured spectrophotometrically (Spectramax 190; Molecular 
Devices, Sunnyvale, CA, USA) at the wavelength most appropriate for each drug (Table A, 
Supporting Information). Fluorescence measurements of the hydrophilic markers were 
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performed using a Polarstar fluorimeter (Fluostar, BMG Technologies, Offenburg, Germany) 
with excitation and emission wavelengths at 485 and 520 nm, respectively. A blank consisting 
of the same phosphate buffer as that used to prepare the drug solutions was subtracted from the 
absorbance/fluorescence values. The standard curves were derived from 11 different points (for 
the concentration range, see Table A, Supporting Information), and each point represented the 
mean of six parallels. The resistance of the lipid barriers was measured (Millicell-ERS, 
Millipore, Billerica, MA, USA) immediately after completing the permeation studies. A value 
of 119 ohms was subtracted from the observed resistance of the filters to account for the 
background resistance of the lipid barrier alone. The mean values and standard deviations are 
reported.  
 
Calculations of physicochemical properties 
QikProp, version 3.4, (2011)(Schrödinger, LLC, New York, NY, USA) was used with Maestro, 
version 9.2.112, to calculate the absorption percentage in the gastrointestinal tract as well as 
Mw and log P of the drugs. All substances were within the structural limits of the program. 
 
Modifications of the PVPA barrier lipid composition to better mimic the intestinal 
epithelia  
To produce barriers that could potentially mimic the lipid composition found in vivo in intestinal 
epithelia to a greater extent as well as to provide a more robust system capable of withstanding 
harsher procedural conditions8,22,24, permeation barriers were prepared from liposomes 
containing the following: 26% phosphatidylcholine (PC), 26.5% phosphatidylethanolamine 
(PE), 7% phosphatidylserine (PS), 7% phosphatidylinositol (PI) and 33% cholesterol.  
To prepare tight permeation barriers with the new lipid compositions, the original preparation 
process presented above required alterations. The different parameters investigated in the 
preparation process were as follows: i) the centrifugation time and speed after the addition of 
the small and large liposomes, respectively, ii) the temperature and duration of heating during 
the freeze-thaw cycling, iii) the number of freeze-thaw cycles, iv) the concentrations of the 
liposome dispersion, and v) the use of evaporation instead of centrifugation to settle the larger 
liposomes on the filter support. The permeability of the hydrophilic marker calcein as well as 
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the electrical resistance across the barriers were used to monitor the effects of changing the 
different parameters on the barrier properties.12 
 
Stability of the PVPA in the presence of tensides and co-solvents 
The stability of the PVPA barriers in the presence of tensides and co-solvents was examined to 
determine the feasibility of using these models in estimating the permeability of poorly soluble 
compounds of interest. The permeability of calcein and the electrical resistance across the 
barriers, markers previously used to indicate barrier integrity, were used to monitor the effect 
of the presence of additives in different concentrations.12,25 The surfactants were each used at 
concentrations greater than their critical micelle concentration (CMC). PBS was included as a 
control and Triton X, which highly solubilizes liposomes, was included as a reference. 
 
Statistical analysis 
To determine if the changes in the preparation procedure provided significant changes in the 
permeability values, Student’s t-tests for the comparison of two means were performed. A 
significance level of p<0.05 was consistently used. The hypotheses determined the choice of a 
one- or two-sided t-test. 
 
RESULTS AND DISCUSSION 
Comparison of the experimental permeation values obtained from the PVPA with the 
calculated values of absorption and lipophilicity 
The original PVPA (PVPAo) was first compared with an in silico model for the estimation of 
permeability. A selection of 25 drugs, chosen to cover both acidic, basic and neutral drugs as 
well as a wide range of fractions absorbed in humans, was made. The results from the 
permeability values experimentally obtained from the PVPAo together with the calculated 
values for absorption as well as the molecular descriptors for the selection using QikProp are 
presented in Table 1. 
The PVPA provided a means through which to classify the compounds into poor, moderate and 
excellent absorption categories according to their permeability values in the assay. At pH 7.4, 
compounds with Papp-values <0.1×10
−6 cm/s are poorly absorbed (<30% fraction absorbed in 
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vivo), compounds with Papp-values between 0.1 and 0.9×10
−6 cm/s are moderately absorbed 
(30–70% fraction absorbed in vivo), and compounds with Papp-values of >0.9×10
−6 cm/s have 
excellent oral absorption (>70% fraction absorbed in vivo).12 Based on this classification, 22 of 
the 25 drugs, or approximately 90%, were correctly classified with the PVPAo (salicylic acid, 
sulphasalazine and tranexamic acid were incorrectly classified). In comparison, only 19 of the 
25 were correctly classified based on the QikProp-calculated absorbed fractions. When 
comparing the calculated fraction absorbed with the in vivo data (Figure A, Supporting 
Information), the calculated values appeared elevated relative to the in vivo data for the drugs 
with low absorption, while the opposite was seen for the drugs with high absorption in vivo. 
The experimentally determined log D and calculated log P did not demonstrate a correlation 
with in vivo fraction absorbed  for this selection of drugs, as has been observed for other 
selections of drugs.12  
The PVPAo thus appears capable of predicting intestinal absorption for marketed drugs with a 
degree of accuracy that is significantly better than theoretical models. The next step was thus 
to investigate if the use of more biologically relevant pH conditions and a biomimetic lipid 
barrier composition could further improve the model. 
 
Investigation of various pH conditions representative of the different intestinal regions 
The goal of an in vitro permeability model is to generate permeability values that correlate 
significantly with in vivo permeability data. To reach this ambition, it is important that the 
model mimics the in vivo situation as closely as possible. A factor receiving much attention in 
this respect is the pH profile of the gastrointestinal tract.26 
The pH in the gastrointestinal tract increases from the acidic environment of the stomach to the 
more basic environment of the large intestine. In addition, the pH differs under fasting and fed 
conditions. The median pH in the duodenum has been reported to be 6.1 in the fasted state, with 
a decrease to pH 5.4 during a meal.27 Between the proximal jejunum and the distal ileum, the 
pH gradually increases from approximately 6 to approximately 8.26 
This provides a challenge when considering an estimation of permeability. To achieve a better 
understanding of drug permeability in vivo, the models must maintain their integrity across the 
pH range normally found in the intestine, and investigations into how changes in pH influence 
drug permeability are of high interest. 
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The integrity of the original PVPA barriers across a pH range from 2.0 to 8.0 was previously 
reported, and the barriers were found to maintain their integrity in terms of unchanged 
permeability of the hydrophilic marker fluorescein as well as electrical resistance.25 The 
permeabilities of metoprolol and naproxen have also been shown to decrease with increasing 
ionization, according to the pH partition hypothesis. The model has thus shown useful potential 
in monitoring pH as an influencing factor in respect to the permeability of drugs and providing 
information about segmental absorption in the gastrointestinal tract.15 
The permeability values of the 25 selected drug compounds, containing acidic, basic and neutral 
compounds, were evaluated by comparing those with pH 6.2 in the donor compartment with 
those obtained with pH 7.4 in the donor chamber (see Figure 1 and Table 1). It is apparent that 
some drugs showed the same permeation, independent of pH, while the basic drugs were mostly 
found in the dark grey triangle and the acidic drugs are mostly found in the light gray triangle, 
as expected according to the pH partition hypothesis. The degree of correct classification 
according to the in vivo absorption determined using the previously suggested classification 
system12 were, however, not significantly different for the two pH conditions. However, this 
classification was set based on data obtained at pH 7.4, so the fact that the more biorelevant pH 
6.2 did not lead to a higher degree of correct classification is not necessary surprising. One 
could suggest narrowing the range of the moderate absorption category to compounds with Papp-
values between 0.1 and 0.7×10−6 cm/s. This would lead to no difference in the degree of correct 
classification for the drugs at pH 6.2 but would lead to the misleading classification of 
cimetidine (Fa=64%) at pH 7.4 into the class of excellent absorbed drugs. 
 
Biomimetic PVPA (PVPAbiomimetic) 
Lipoid E-80 with 82% (w/w) phosphatidylcholine (PC), 9% phosphatidylethanolamine (PE), 
3% lysophosphatidylcholine, 2% sphingomyelin, 3% triglycerides, and 1% cholesterol was 
previously used in the development of the assay.12 In this study, we aimed to adapt the model 
to better resemble in vivo conditions by changing the lipid composition of the barrier to one that 
more closely mimics the lipid composition of intestinal cells. It has been shown that membranes 
consisting of only PC are underestimating the permeability of basic and acidic drugs and that a 
better in vivo-in vitro correlation is obtained by using a negatively charged barrier with a 
biomimetic lipid composition of 26% PC, 26.5% phosphatidylethanolamine (PE), 7% 
phosphatidylserine (PS), 7% phosphatidylinositol (PI) and 33% cholesterol.8,22 Utilizing this 
biomimetic lipid barrier composition in the PVPA, we investigated whether the alterations 
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significantly affected the permeation of drugs and if this new composition could improve the 
accuracy of the assay. 
Development of preparation procedure 
The basis for the development of a suitable preparation procedure for the new biomimetic 
PVPA barriers containing PC/PE/PS/PI/Chol stemmed from the original preparation method 
for PVPA barriers composed of E-80. 
Liposomes composed of PC/PE/PS/PI/Chol were extruded through filters with pore sizes of 
600 and 1200 nm to yield populations with mean sizes of 367 nm and 901 nm, which were 
entered into the pores of the filter and layered on top of the filter support, respectively. The zeta 
potentials were found to be -1.13 ± 0.25 mV and -20.95 ± 0.52 mV for the E-80 liposomes and 
the liposomes composed of PC/PE/PS/PI/Chol, respectively. This demonstrates that the chosen 
lipid composition results in liposomes with a negative surface charge, which are expected to 
produce barriers with the same property. 
By applying the original preparation procedure described above to the liposomes composed of 
PC/PE/PS/PI/Chol, highly leaky barriers, characterized by high calcein permeability, were 
obtained. The follow parameters were thus investigated to obtain tighter barriers: i) the 
centrifugation time and speed after addition of small and large liposomes, respectively, ii) the 
temperature and duration of heating during freeze-thaw cycling and iii) the number of freeze-
thaw cycles. Unfortunately, these approaches did not result in tight barriers (see Supporting 
Information for details), indicating that the original preparation procedure using centrifugation 
to immobilize the liposomes was not a promising approach. This can most likely be attributed 
to less efficient packing of the liposomes in the pores and on top of the barrier than in the 
original barriers. 
An attempt was therefore made to use the original method of using small liposomes of E-80 to 
fill the pores. This was followed by the addition of larger liposomes with the biomimetic lipid 
composition, centrifugation at 2500 rpm for 30 min to settle the liposomes on top of the filter 
and invert centrifugation at low speed to remove the buffer. Freeze thaw cycles were performed 
as in the original procedure, with thawing at 60 °C for 60 min. The obtained barriers exhibited 
a permeation value for calcein of 2.307 x 10-6 cm/s (procedure 1, Figure 2), which was an 
improvement; however, the assay still lacked satisfactory integrity. 
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The next step was to omit the invert centrifugation step after allowing the larger liposomes 
consisting of PC/PE/PS/PI/Chol to settle and instead remove the buffer by evaporation at 50 °C 
for 60 min: a strategy that has been successfully used for the preparation of PVPA barriers 
composed of skin lipids.21 This approach (procedure 2, Figure 2) resulted in tighter barriers 
with a mean permeation of calcein of 0.063 x 10-6 cm/s. Furthermore, the addition of the larger 
liposomes without centrifugation before the evaporation step was tested. The results (procedure 
3, Figure 2) show a mean permeation of calcein of 0.073 x 10-6 cm/s, indicating that 
centrifugation does not provide significantly tighter packing for the larger liposomes and could 
thus be skipped to simplify the procedure. 
The influence of using a 6% liposome dispersion, as in the original preparation procedure, 
instead of a 3% liposome dispersion on the tightness of the barriers was also investigated. The 
resulting calcein permeability and electrical resistance across the different barriers (procedure 
3 vs. 4 in Figure 2) surprisingly showed no significant differences; therefore, 3% was kept as 
the concentration for the liposome dispersion in the final preparation procedure. This avoids 
the use of extensive amounts of lipids and reduces the total cost of the model. 
Furthermore, an attempt to use a lower thawing temperature over a prolonged time period was 
evaluated. Both 50 °C for 105 min (procedure 5, Figure 2) and 30 °C for 270 min (procedure 
6, Figure 2) were analyzed to elucidate their impact on barrier tightness. Procedure 5 resulted 
in barriers with a mean calcein permeability of 0.052 x 10-6 cm/s, while procedure 6 resulted in 
barriers with a mean calcein permeability of 0.026 x 10-6 cm/s. Both procedures showed high 
reproducibility, as reflected in their low standard deviations. However, even though procedure 
6 resulted in slightly tighter barriers, the faster and simpler preparation protocol of 50 °C for 
105 min was chosen for the final preparation process. 
Based on the obtained results and an evaluation of feasibility with respect to cost and time 
consumption, the final preparation procedure for PVPAbiomimetic barriers is summarized as 
follows: 
 Addition of small (extruded through 400 nm pore filter) liposomes of E-80 (6%; w/v) 
to fill the pores of the filter: 100 µl of liposomes was added and centrifuged at 2000 rpm 
(950 g) for 5 min; the  procedure was repeated with centrifugation extended to 10 min 
 Heating at 50 °C for 45 min 
 Addition of large (extruded through 1200 nm pore filter) liposomes of 
PC/PE/PS/PI/Chol (3%; w/v) to settle on top of the filter support:  
13 
 
o 50 µl of liposomes was added, the solvent was allowed to evaporate in 50 °C 
incubator for 30 min, and the procedure was performed twice. 
 Freezing at -70 °C for minimum 60 min 
 Heating at 50 °C for 105 min  
The barriers prepared by this procedure exhibited calcein permeability of 0.052 x 10-6 ± 0.016 
x 10-6 cm/s. In summary, the major changes from the original PVPA were i) the exchange of 
centrifugation for evaporation as the method to settle the large liposomes on top of the filter 
support and ii) the performance of thawing in the freeze-thaw step at a lower temperature over 
a longer duration of time. 
Evaluation of the biomimetic PVPA 
From the zeta potential measurements, it was evident that the PVPAbiomimetic barrier had a net 
negative charge. This is in contrast to the PVPAo barrier made from egg PC that exhibited no 
net charge. It was thus expected that the permeability of the charged compounds would be more 
affected than that of the neutral compounds in the new PVPAbiomimetic compared to PVPAo. A 
negatively charged barrier is expected to increase the affinity of basic compounds for the 
barrier. Moreover, the negative charges on the surface of the barrier can reduce the pH close to 
the surface and thus increase the permeability of acidic drugs.8,22 On the other hand, the surface 
potential that arises from charged lipid head groups at the barrier surface can also attract counter 
ions from the buffer to the interface, giving rise to a so-called electrical double layer and the 
establishment of an electric potential profile at the barrier surface. The surface potential would 
not have an effect on the permeation of neutral species through the bilayer; however, positively 
charged compounds would be attracted, thus increasing the surface concentration and giving 
rise to a higher probability of permeation. The opposite should be the case for negatively 
charged compounds, and the probability of permeation should decrease.28  
The newly developed PVPAbiomimetic was evaluated by performing permeability experiments at 
pH values of 6.2 and 7.4 for a selection of 19 drugs chosen to cover acidic, basic and neutral 
drugs as well as a wide range of fractions absorbed in humans. The results are displayed in 
Table 2. The drugs salicylic acid and sulphasalazine, which were incorrectly classified in the 
PVPAo, were included in this selection of compounds to challenge the new model.  
As expected, at pH 7.4, the positively charged, basic compounds showed a general increase in 
permeability through the biomimetic barriers compared to the barriers made from PC only. No 
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clear trend was evident for the negatively charged, acidic compounds; the permeabilities 
increased, decreased and were unchanged relative to the PVPAo. This was also the case for a 
selection of acids tested in the PAMPA model using a biorelevant lipid composition, as reported 
by Sugano and colleagues.22 For the neutral compound, a decrease in permeability was 
observed; however, because the permeability values observed in both models were very high, 
there was no significant difference regarding the drug classification. 
When comparing the PVPAbiomimetic with the PVPAo, the same drugs that were incorrectly 
classified in the PVPAo were also incorrectly classified in the PVPAbiomimetic. In addition, 
nadolol, a positively charged compound that, as expected, exhibited increased permeability 
through the negatively charged barriers, showed a Papp-value that indicated excellent absorption 
in vivo while the correct class should be moderate absorption. This was the only drug for which 
the PVPAo performed better than the PVPAbiomimetic.  
The PVPAbiomimetic also proved to be stable at pH 6.2, based on the permeability of calcein and 
the electrical resistance across the barriers (Table 2). The permeation of the drugs at different 
pH conditions was consistent with the pH partition hypothesis, with increased permeability of 
acidic drugs and decreased permeability of basic drugs at pH 6.2 compared to pH 7.4. Both pH 
conditions elicited the same degree of correct classification into the in vivo absorption 
categories, with the exception of timolol, which demonstrated the expected decrease in 
permeability at pH 6.2 compared to that at pH 7.4 but resulted in a Papp value of 0.8 x 10
-6 cm/s, 
which falls below the limit of 0.9 x 10-6 cm/s originally required to be correctly classified into 
the excellent absorption category in vivo. However, when using the narrowed range of 
permeability values giving the moderate absorption category as discussed above, timolol would 
also be correctly classified as having excellent absorption at pH 6.2. However, this would 
additionally classify the moderately absorbed drugs atenolol and sulpiride into the excellent 
category at pH 7.4. 
 
Stability of the biomimetic PVPA in the presence of tensides and co-solvents 
Investigation into the biomimetic barriers’ integrity in the presence of tensides and co-solvents 
was performed to determine the feasibility of estimating the permeability of poorly soluble 
compounds. Calcein permeability and electrical resistance, both indicators of barrier integrity, 
were measured in the presence of three co-solvents and six tensides, as reported in Table 3.  
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The presence of the co-solvents ethanol, DMSO and PEG 400 did not induce any significant 
change in calcein permeability in all concentrations tested, indicating the retained integrity of 
the permeation barriers under these conditions. Similar results were previously shown for the 
PVPAo.
25 However, in respect to the effect of the tensides, the PVPAbiomimetic appears to be 
significantly more robust than the PVPAo, which is a promising and important finding carrying 
the model forward. The presence of Poloxamer 188 evoked no significant change in the 
permeability of calcein up to 60 mg/ml and the presence of Span 20 resulted in no significant 
change at a concentration of 20 mg/ml. The presence of Tween 80, Brij 35 and Cremophor EL 
induced statistically significant increases in the permeability of calcein. However, this increase 
was small and the electrical resistances remained within the limits set for the barriers to indicate 
a maintenance of integrity (1000 ohm/insert).12 It has also been previously stated that the 
PVPAo barriers are considered to be stable up to a calcein permeability of approximately 
0.15×10−6 cm/s.29 Even Triton X, included as a reference due to its known efficiency in 
solubilizing phospholipids, showed a permeability value of calcein below this limit. This is a 
tremendous increase in barrier integrity stability compared to the PVPAo, where even the lowest 
examined concentrations of tensides resulted in a 10-20-fold increase in calcein permeability 
as well as electrical resistance values below 500 ohm.19,25,29 The reason for this increased 
stability is most likely the presence of cholesterol, which is known to increase the rigidity of 
the bilayer and hence the stability towards solubilization by tensides.30  
It is, however, important to consider the solubility-permeability interplay when estimating the 
permeability of poorly water-soluble drugs in solubility-enhancing formulations.31 Apparent 
permeability has been shown to decrease with an increase in solubility through the use of both 
surfactants and co-solvents: the first due to a reduced fraction of free drug and the latter due to 
a change in the distribution coefficient.31,32 The reduction in the drugs thermodynamic activity, 
and thereby permeability, by formulating poorly water-soluble drugs using tensides has also 
been demonstrated with the PVPA.19 
The highly increased stability in the presence of tensides is, however, a very promising finding 
that renders the PVPAbiomimetic much more suitable to also estimating the permeability of poorly 





To improve the PVPA to more closely mimic the in vivo situation in the GI tract, the pH was 
changed to a more biologically relevant pH of 6.2 and the barrier lipids altered to a biomimetic 
lipid composition. The lipid composition as well as the barrier preparation procedure has been 
optimized, resulting in the successful development of permeation barriers with an intestinal-
mimicking lipid composition that exhibit low permeability of hydrophilic markers and the 
ability to distinguish between substances with varying degrees of intestinal absorption. 
Positively charged basic compounds showed increased permeability through the negatively 
charged biomimetic barriers, as expected. The degree of correct classification according to in 
vivo absorption was comparable for the PVPAo and the PVPAbiomimetic. Importantly, the 
PVPAbiomimetic appears to be significantly more robust towards the presence of tensides 
compared to the PVPAo, which is a very promising and important finding rendering the 
biomimetic PVPA much more suitable to estimating the permeability of poorly soluble 
compounds of interest and thus carrying the model an important step forward. 
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1. Correlation of the permeability values obtained at pH 6.2 vs. 7.4 in the donor compartment. 





Figure 2. Apparent permeability (Papp) of calcein and electrical resistance across barriers 
prepared with different parameters. The different procedures represent changes in the 
following parameters: 
1) 2500 rpm with large liposomes (3%) x 2, invert centrifugation, thawing at 65 °C for 30 min 
2) 2500 rpm with large liposomes (3%)  x 2, heating at 50 °C for 60 min, thawing at 60 °C for 60 min 
3) Addition of large liposomes (3%), heating at 50 °C for 30 min x 2, thawing at 60 °C for 60 min 
4) Addition of large liposomes (6%), heating at 50 °C for 30 min x 2, thawing at 60 °C for 60 min 
5) Addition of large liposomes (3%), heating at 50 °C for 30 min x 2, thawing at 50 °C for 105 min 
6) Addition of large liposomes (6%), heating at 50 °C for 30 min x 2, thawing at 30 °C for 270 min 
 
  
Table 1. Experimental Papp-values from the PVPAo at pH 6.2 and 7.4, molecular properties 
and calculated and experimental literature values of percent absorption in humans (Fa)  
Compound PVPAo  Mw logP Fa logDa pKab Fa c 
 Papp±SD 10-6 cm/s  calc calc 
% 
   
% 
 pH 6.2 pH 7.4d       
Acetylsalicylic 
acid 
1.95±0.65 1.49±0.23 180.2 1.19 72 -2.25 3.51 1006 
Alprenolol 1.57±0.09 4.92±0.34 249.4 3.07 97 1.38 9.21 935 
Atenolol 0.18±0.01 0.22±0.05 266.3 -0.42 55 -1.29 9.51 505 
Caffeine 6.24±0.17 6.04±0.5711 194.2 0.16 81 0.02 - 1007 
Chlorothiazide 0.04±0.01 0.03±0.00 295.7 -0.07 52 -0.05 6.72 134 
Chlor-
amphenicol 
1.57±0.25 1.81±0.07 323.1 1.07 64 1.14 5.52 902 
Cimetidine 0.40±0.05 0.89±0.05 252.3 -0.25 72 0.35 6.91 642 
Diclofenac 3.05±0.14 2.71±0.1613 296.2 0.42 100 1.15 4.02 1002 
Enalapril 0.35±0.03 0.14±0.01 492.5 4.50 52 -0.90 2.9/5.21 654 
Flurbiprofen 8.72±0.34 6.24±0.3013 244.3 0.26 96 0.911 4.031 958 
Flufenamic acid 1.61±0.14 1.68±0.5910 281.2 5.23 89 2.451 4.091 -8 
Hydro-
chlorothiazide 
0.44±0.06 0.51±0.06 297.7 4.16 53 -0.12 8.9/10.31 674 
Ibuprofen 13.34±0.97 8.42±0.8610 206.3 -0.09 92 0.68 4.451 958 
Metoprolol 1.26±0.33 3.23±0.78 267.3 3.50 89 -0.16 9.61 955 
Metronidazol 4.34±0.12 3.92±0.2513 171.2 1.89 92 -0.021 - 100 
Nadolol 0.54±0.10 0.70±0.11 309.4 -0.02 67 0.68 9.71 354 
Naproxen 10.17±0.40 8.73±0.61 9 230.3 0.80 90 0.23 4.153 992 
Propranolol 1.18±0.17 3.41±0.4113 259.3 3.09 97 1.411 9.522 904 
Ranitidine 0.11±0.02 0.24±0.01 350.9 3.18 70 -0.29 8.3/2.11 505 
Salicylic acid 0.45±0.04 0.59±0.03 138.1 3.09 76 -1.44 3.01 1005 
Sulphasalazine 0.48±0.16 0.60±0.18 398.4 0.78 50 -0.42 2.8/8.3/ 
11.01 
135 
Sulpiride 0.35±0.07 0.22±0.01 341.4 2.26 61 -1.00 9.02 356 
Terbutaline 0.80±0.09 0.40±0.05 274.3 1.67 62 -1.35 8.7/10.0/ 
11.01 
622 
Timolol 1.65±0.08 1.70±0.12 316.4 0.09 84 0.03 9.51 904 
Tranexamic 
acid 
5.34±0.46 12.36±3.64 157.2 3.31 43 -3.00 4.5/10.72 552 
Calcein - 0.061±0.005 622.5 -1.71 - - 1.8/9.212 - 
a The log D values are from (Zhu et al., 2002). (Avdeef, 2004)1 
b The pKa values are from (Avdeef, 2004)1, (Sugano et al., 2002)2 , (Li et al., 2012)3,  (Flaten et al., 2006)12 
c (Sugano et al., 2001)4, (Yazdanian et al., 1998)5, (Kansy et al., 1998)6, (Sugano et al., 2002)2, (Yee, 1997)7, 
(Osterberg et al., 2001)8 
d The Papp values are taken from (Flaten et al., 2006) unless stated otherwise;(Flaten et al., 2008)9,  
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Table 2. Experimental Papp values from the PVPAbiomimetic at pH 6.2 and 7.4, molecular 
properties and fraction absorbed (F%) in humans. 
Compound PVPAbiomimetic Mw Charge at pH 
6.2 




-6 cm/s    % 
 pH 6.2 pH 7.4     
Alprenolol 1.07±0.04 1.59±0.07 249.4 + + 93 
Atenolol 0.49±0.06 0.76±0.11 266.3 + + 50 
Caffeine 4.04±0.08 4.32±0.28 194.2 0 0 100 
Chlorothiazide 0.07±0.01 0.05±0.01 295.7 0 - 13 
Diclofenac 4.25±1.00 2.23±0.39 296.2 - - 100 
Enalapril 0.42±0.04 0.43±0.05 492.5 - - 65 
Flurbiprofen 5.77±0.57 3.26±0.57 244.3 - - 95 
Ibuprofen 12.11±1.98 9.01±1.45 206.3 - - 95 
Metoprolol 1.23±0.18 1.61±0.45 267.3 + + 95 
Metronidazol 3.31±0.36 3.15±0.27 171.2 0 0 100 
Nadolol 1.47±0.09 1.55±0.13 309.4 + + 35 
Naproxen 5.63±0.33 3.79±0.30 230.3 - - 95 
Propranolol 0.89±0.08 1.76±0.11 259.3 + + 90 
Ranitidine  0.25±0.02 0.40±0.07 350.9 + + 50 
Salicylic acid 0.69±0.02 0.54±0.01 138.1 - - 100 
Sulphasalazine 0.46±0.02 0.20±0.02 398.4 - - 13 
Sulpiride 0.37±0.03 0.89±0.08 341.4 + + 35 
Terbutaline 0.50±0.13 0.64±0.11 274.3 + + 62 
Timolol 0.79±0.03 1.57±0.02 316.4 + + 90 
       
Calcein 0.08±0.003 0.05±0.002 622.5 - - - 





Table 3. The permeability (Papp) values for calcein ± SD (10
-6 cm/s), together with the electrical 
resistances across the PVPA barriers (ohm) in the presence of the tensides and co-solvents 
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DMSO - - - 
0.053 
±0.012 
[1585] 
0.094 
±0.022 
[1448] 
- 
0.078 
±0.019 
[1544] 
- 
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